Skip to main content

Table 3 Tractional retinal detachment characteristics following injection of Ranibizumab 1 and 3 days prior to diabetic vitrectomy

From: The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage

Time point Group A Group B Group C
Baseline 3 days Baseline 1 days Baseline 3 days
TRD characteristics from ultrasound
 Number of eyes with TRD 13(81.25%) 13(81.25%) 12(75%) 12(75%) 11(68.75%) 11(68.75%)
 Number of eyes with macula TRD 9(56.25%) 9(56.25%) 7(43.75%) 7(43.75%) 7(43.75%) 7(43.75%)
Dimensions of TRD (mean (SD))
  Height (mm) 2.1 (1.7) 2.2 (1.7) 1.9 (1.7) 1.8 (1.7) 2.1 (1.6) 2.3 (1.9)
  Base (mm) 6.7(5.4) × 6.8(5.1) 7.0(5.9) × 6.8(5.1) 7.4(5.3) × 6.3(4.7) 7.4(5.5) × 5.7(4.1) 8.2(5.0) × 8.5(5.3) 8.4(5.2) × 8.7(5.3)
Intraoperative TRD
  Absent 3   2   3  
  Hammock 4   4   2  
 Diffuse central 3   3   3  
  Tabletop 3   3   3